

## **AMENDMENT TO THE CLAIMS**

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

### **In the Claims:**

1. (Currently amended) A bioadhesive pharmaceutical dosage form which can be administered nasally and is in film form, comprising ~~in~~ at least one lidocaine active ingredient-containing layer based on crosslinked hydrophilic polymers from 30% by weight to 60% by weight of lidocaine, based on the total amount of crosslinked hydrophilic polymers, ~~and that it~~

wherein the dosage form has a tear strength of at least 40 N and

the hydrophilic polymer of the active ingredient-containing layer has been crosslinked in situ and  
the ratio of hydrophilic polymers to crosslinker is from 2:1 to 5:1 by weight.

2. (Currently amended) The dosage form as claimed in claim 1, characterized in that the dosage form ~~it~~ has a tear strength, preferably of at least 50 N, ~~particularly preferably of at least 60 N.~~

3. (Currently amended) The dosage form as claimed in claim 1, characterized in that a cellulose ether, preferably hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and/or hydroxypropylmethylcellulose, cellulose ether has been used as hydrophilic polymer.

4. (Currently amended) The dosage form as claimed in claim 1, characterized in that the dosage form has a tear strength of at least 60 N, the hydrophilic polymer of the active ingredient containing layer has been crosslinked in situ.

5. (Currently amended) The dosage form as claimed in claim 1, characterized in that the dosage form ~~it~~ exhibits controlled release of lidocaine.

6. (Currently amended) The dosage form as claimed in claim 1, characterized in that the dosage form ~~it~~ is monolayer or multilayer.

7. (Currently amended) The dosage form as claimed in claim 6, characterized in that the dosage form ~~it~~ has at least one active ingredient-containing layer, one covering layer and/or one adhesive layer.

8. (Original) The dosage form as claimed in claim 7, characterized in that one active ingredient-containing layer is the adhesive layer.

9. (Previously Presented) The dosage form as claimed in claim 7, characterized in that the covering layer is impermeable for the active ingredient.

10. (Currently amended) ~~The use of a lidocaine-containing layer in film form based on crosslinked hydrophilic polymers with from 30% by weight to 60% by weight of lidocaine for producing a monolayer or multilayer pharmaceutical dosage form having a tear strength of at least 40 N which can be administered nasally and is in film form A method for controlling primary headaches in humans which comprises of administering a therapeutically effective amount of the bioadhesive pharmaceutical dosage form of claim 1.~~

11. (Currently amended) ~~The use as claimed in claim 10 for controlling The method of claim 10, wherein the control of primary headaches is via controlling neurovascular pain.~~

12. (Currently amended) ~~The use as claimed in claim 10 for controlling The method of claim 10, wherein the control of primary headaches is reduces the effect of a migraine.~~

13. (New) The dosage form as claimed in claim 3, characterized in that the cellulose ether is selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.

14. (New) The dosage form as claimed in claim 4, characterized in that the cellulose ether is selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.